Alnylam Pharmaceuticals CEO Discusses Q3 2010 Results ¿¿ Earnings Call Transcript

Alnylam Pharmaceuticals, Inc. (ALNY)

Q3 2010 Results Conference Call

November 3, 2010 4:30 PM ET

Executives

Cynthia Clayton – Senior Director of IR and Corporate Communications

John Maraganore – CEO

Akshay Vaishnaw – SVP, Clinical Research

Patty Allen – VP of Finance and Treasurer

Barry Greene – President and COO

Analysts

Marko Kozul – ThinkEquity

Ted Tenthoff – Piper Jaffray

Keay Nakae – Chardan Capital

Alan Carr – Needham & Company

Steven Willey – Stifel Nicolaus

Presentation

Operator

Compare to:
Previous Statements by ALNY
» Alnylam Pharmaceuticals, Inc. Q2 2010 Earnings Call Transcript
» Alnylam Pharmaceuticals, Inc. Q1 2010 Earnings Call Transcript
» Alnylam Pharmaceuticals, Inc. Q4 2008 Earnings Call Transcript
» Alnylam Pharmaceuticals, Inc. Q3 2008 Earnings Call Transcript

Ladies and gentlemen, thank you for standing by. Welcome to the Alnylam Pharmaceuticals conference call to discuss the third quarter 2010 activities and financial results.

There will be a question-and-answer session to follow. Please be advised that this call is being taped at the company’s request.

I’d now like to hand the call over to Alnylam.

Cynthia Clayton

Good afternoon. I’m Cynthia Clayton, Senior Director of Investor Relations and Corporate Communications at Alnylam. With me today are John Maraganore, our Chief Executive Officer; Barry Greene, our President and Chief Operating Officer; Akshay Vaishnaw, Senior Vice President, Clinical Research; and Patty Allen, Vice President of Finance and Treasurer. In addition, Laurence Reid, our Chief Business Officer is also on the call and available for Q&A.

For those of you participating via conference call, the slides we have made available via webcast can also be accessed by going to the Investors page of our website, www.alnylam.com.

During today’s call, as outlined on Slide 2, John will provide some introductory remarks and general context, Akshay will summarize our clinical and preclinical R&D activities, Patty will review our financials and guidance, and Barry will summarize our business highlights and goals. We will then open the call for your questions.

1 2 3 Next › Last »